AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06639633 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anatomy Training with Enlarged %50 3D Printed Carpal Model Group
Description: After completing the general terminology part of the anatomy education in the first year, the participants will be recruited without moving on to the hand section of the upper extremity. Participants will undergo a 2-hour extra-curricular training, 60 minutes theoretical and 30 minutes practical. The training period will consist of 60 minutes of practical and theoretical lectures to be the same as the time allocated in the normal curriculum of the region. A 60-minute theoretical lecture on the anatomy of the carpal bone supported by 2-dimensional anatomical pictures will be given to both groups at the same time. Then they will take the practical lesson with carpal bones printed with 50% magnification on a 3D printer for 60 minutes.
Study NCT06639633 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anatomy Training with Conventional Carpal Models
Description: After completing the general terminology part of the anatomy education in the first year, the participants will be recruited without moving on to the hand section of the upper extremity. Participants will undergo a 2-hour extra-curricular training, 60 minutes theoretical and 60 minutes practical. The training period will consist of 60 minutes of practical and theoretical lectures to be the same as the time allocated in the normal curriculum of the region. A 60-minute theoretical lecture on the anatomy of the carpal bone supported by 2-dimensional anatomical pictures will be given to both groups at the same time. They will then have a 60 minutes practical lesson with a standard sized printed model.
Study NCT05085028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/ML [Keytruda]
Description: Pembrolizumab to be given at 400mg intravenous over 5 different frequencies
Study NCT05085028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab 25 MG/ML [Keytruda]
Description: Pembrolizumab to be given at 400mg intravenous over 5 different frequencies
Study NCT05098548 — intervention group
Intervention type: PROCEDURE
Intervention: angioplasty
Description: using a balloon to stretch open a narrowed or blocked artery. However, most modern angioplasty procedures also involve inserting a short wire-mesh tube, called a stent, into the artery during the procedure. The stent is left in place permanently to allow blood to flow more freely .
Study NCT05697718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: a single injection dose i.v.
Study NCT05644873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulfate group
Description: Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.
Study NCT05644873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control group saline
Description: Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
Study NCT04958863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical mask
Description: Use of a surgical mask during test
Study NCT04958863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyester reusable mask
Description: Use of a polyester reusable mask during test
Study NCT05177250 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HPLC
Description: taking urine samples from participants and analyze these samples to detect bisphenol A and paraben
Study NCT06183398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin prick test
Description: Specific skin prick tests for 6 raw food: peach, apple, sesame, carrot, lemon and orange
Study NCT04575272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided continuous serratus anterior plane block
Description: Local anesthetic infusion though a peripheral nerve catheter placed related to the serratus anterior muscle at the level of the 5th rib
Study NCT04575272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided continuous serratus anterior plane block
Description: Local anesthetic infusion though a peripheral nerve catheter placed related to the serratus anterior muscle at the level of the 5th rib
Study NCT06137365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis gummy product will be prepared using cannabis flower extract.
Study NCT06137365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gummy product will be prepared using the same ingredients as the cannabis gummy but will not contain active cannabinoids.
Study NCT04088903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: >Daratumumab 16 mg/kg intravenous weekly for 8 weeks and then every other week for 2 doses.
Study NCT05489328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Candidate-1
Description: Biological
Study NCT05489328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Candidate-2
Description: Biological
Study NCT05489328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Candidate-3
Description: Biological
Study NCT05489328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Candidate-4
Description: Biological
Study NCT05489328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Candidate-5
Description: Biological
Study NCT05489328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Candidate-6
Description: Biological
Study NCT05489328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Candidate Control
Description: Biological
Study NCT05489328 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 13vPnC
Description: 13-valent pneumococcal conjugate vaccine
Study NCT05522673 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 11(R)-rolipram
Description: Injected IV followed by PET scanning
Study NCT05489328 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV15
Description: 15-valent pneumococcal conjugate vaccine
Study NCT05355727 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical decision support tool recommended outcome
Description: The PROSAIC-DS tool will take the variables and produce a suggested outcome. It will supply supporting evidence and best practice for its recommendations
Study NCT06345885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Description: Participants in the group A will be administrated with bivalent HPV vaccine Cecolin. The immunization schedule is 0, 6 months; Participants in the group B will be administrated with quadrivalent HPV vaccine Gardssil. The immunization schedule is 0, 2, 6 months
Study NCT06345885 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV vaccine
Description: Participants in the group A will be administrated with bivalent HPV vaccine Cecolin. The immunization schedule is 0, 6 months; Participants in the group B will be administrated with quadrivalent HPV vaccine Gardssil. The immunization schedule is 0, 2, 6 months
Study NCT05767281 — intervention group
Intervention type: BEHAVIORAL
Intervention: prevention program
Description: introduction of the developed comprehensive prevention program among the child population with the participation of primary health care personnel, which will improve not only the dental health of children, their quality of life, but will also help reduce foci of chronic oral sepsis.
Study NCT06555211 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: MRI will be performed
Study NCT06555211 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET/CT
Description: PET/CT will be performed
Study NCT05172193 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated
Description: SARS-CoV-2 vaccine (Vero cell) inactivated developed by Beijing Bio-Institute Biological Products Co., Ltd, can induce active immunity and prevent diseases caused by the SARS-CoV-2 virus by producing neutralizing antibody. The inactivated SARSCoV-2 Vaccine (Vero cell) is prepared by inoculating Verda Reno cells (Vero cell) with SARS-CoV-2 HB02 strain, culturing, harvesting, inactivating, clarifying, concentrating, purifying and adding aluminum hydroxide adjuvant.
Study NCT05597280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BE-PEP Bedaquiline
Description: bedaquiline
Study NCT05597280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SDR-PEP Rifampicin
Description: SDR-PEP: rifampicin
Study NCT05597280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BE-PEP Rifampicin
Description: BE-PEP rifampicin
Study NCT05517161 — intervention group
Intervention type: BEHAVIORAL
Intervention: INSIGHT
Description: See Keegan et al., 2020
Study NCT05557448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TYNADOTE
Description: Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
Study NCT05557448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
Study NCT06094907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine
Description: DMT will be administered using a vaporizer device in an ascending fixed-order of 15mg and 60mg.
Study NCT04781881 — intervention group
Intervention type: DRUG
Intervention: Entresto
Description: There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.
Study NCT05701397 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DPD scintigraphy
Description: Bone tracer scintigraphy, diagnostic for transthyretin cardiac amyloidsis
Study NCT04960072 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
Study NCT05268315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Psychoeducational Intervention
Description: The 1-session psychoeducational intervention is divided into three brief modules. Topics that are covered include thinking, learning, emotional, and behavioral functioning as they relate to childhood cancer, educational and school supports, and the role of neuropsychological and school-based assessments.
Study NCT06250517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVLP
Description: The right lung will be perfused for 3h with EVLP
Study NCT06250517 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold preservation
Description: The left lung will be cold preserved as usual protocol
Study NCT05668312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-prehabilitation
Description: Preoperative tele-rehabilitation using a virtual reality system.
Study NCT05668312 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard prehabilitation
Description: Preoperative home-based rehabilitation delivered with a printed booklet for the Con-O subjects and no intervention for the Con-Y subjects.
Study NCT05807386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise programme
Description: A 12 week, online delivered, home-based exercise programme.
Study NCT05714007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose
Description: Single intravenous dose ferric derisomaltose
Study NCT05714007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous succinate
Description: Daily oral dose of 100 mg iron (ferrous succinate) tid postoperatively
Study NCT06146647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive body image TV show
Description: This is a 15 minute (approximately) show that has positive body image content embedded in the storyline. It also showcases a diverse range of body sizes in the casting.
Study NCT06146647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive body image music video
Description: This is a positive body image song with strong visual representation of diverse body sizes in the music video.
Study NCT06146647 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control TV show about a visit to the dentist
Description: 14 minute tv show following a tv character as he visits the dentist.
Study NCT06146647 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control music video about brushing teeth
Description: Music video of a tv character singing about brushing teeth
Study NCT05751759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitiperstat
Description: Participants receive mitiperstat orally.
Study NCT05319834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin tablet
Description: group1: oral aspirin at a dose of 100mg once daily at the same time with progesterone
Study NCT05319834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: group 2: oral placebo once daily at the same time with progesterone
Study NCT05310799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM)
Description: The intervention is a structured SDM discussion between physician and family, occurring at the time of the child's JIA diagnosis and clinic visit. Discussion will be guided by a discussion guide and the PERSON-JIA Report, which is generated in real time on the physician's smart phone.
Study NCT05916521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.454% stannous fluoride
Description: Brush two times daily
Study NCT05916521 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.76% sodium monofluorophosphate
Description: Brush two times daily
Study NCT05916521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM
Description: Brush two times daily
Study NCT05975749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab: 4.5mg/Kg on day 1
Study NCT05975749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzuma
Description: Trastuzuma: 8mg/Kg ( the first cycle)，6mg/Kg (the rest of cycles) on day 1
Study NCT05975749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy: Capecitabine or S-1 and Oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² or S-1 40 mg/m2 twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
Study NCT05975749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy: Capecitabine or S-1 and Oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² or S-1 40 mg/m2 twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
Study NCT05142540 — intervention group
Intervention type: PROCEDURE
Intervention: blood and saliva samples will be taken
Description: For serology, 8 ml of blood and 1.5 ml saliva samples will be taken at every visit.~For testing cellular immunity, additional 24 ml of blood will be drawn at visits 1 and 2.
Study NCT06419452 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Unilateral resistance training programme
Description: A method of training that increases muscle strength and endurance by using external resistance to a unilateral limb or movement.
Study NCT06419452 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bilateral resistance training programme
Description: A training method that increases muscle strength and endurance by using external resistance on both limbs or movements,
Study NCT06419452 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Combined（UL+BL） resistance training programme
Description: A method of training that uses limbs or movements to increase muscle strength and endurance by external resistance using unilateral and bilateral combined forms,
Study NCT05630430 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The Effect of Volar Carbon Plate Applications on Radiation Exposure and Procedure Time in Intra-articular Radius Distal End Fractures
Description: Surgery procedure, Although the bones are at the surgeon's disposal in plate fixation of radius distal end fractures, fluoroscopy is frequently used for reduction control. The increase in the need for scopy both directly affects the duration of the operation and causes the surgical team to be exposed to excessive radiation. Since titanium alloy plates are radiopaque, they create a superposition to the fracture line and more than one view is usually required in each plane to ensure the reduction quality during surgery. Carbon alloy plates, on the other hand, offer the advantage of faster radiological reduction control because they do not create superposition to the fracture line. In our study, in addition to the comparisons in the literature, it is aimed to investigate the effect of carbon plates on the procedure time. surgery time and exposure of radiation will be recorded at the end of the surgery
Study NCT05630430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Effect of Volar Carbon Plate Applications on Radiation Exposure and Procedure Time in Intra-articular Radius Distal End Fractures
Description: Surgery procedure, Although the bones are at the surgeon's disposal in plate fixation of radius distal end fractures, fluoroscopy is frequently used for reduction control. The increase in the need for scopy both directly affects the duration of the operation and causes the surgical team to be exposed to excessive radiation. Since titanium alloy plates are radiopaque, they create a superposition to the fracture line and more than one view is usually required in each plane to ensure the reduction quality during surgery. Carbon alloy plates, on the other hand, offer the advantage of faster radiological reduction control because they do not create superposition to the fracture line. In our study, in addition to the comparisons in the literature, it is aimed to investigate the effect of carbon plates on the procedure time. surgery time and exposure of radiation will be recorded at the end of the surgery
Study NCT00987233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide aqueous nasal spray (Apotex Inc.)
Description: It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
Study NCT00987233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetonide aqueous nasal spray (Nasacort® AQ)
Description: It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
Study NCT06528405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
Study NCT06528405 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other anti-diabetic drug or no anti-diabetic drug
Description: Other anti-diabetic drug or no anti-diabetic drug for 90 days during the acute kidney disease period.~Other anti-diabetic drug includes metformin, sulfonylureas, meglitinides, dipeptidyl peptidase-4 inhibitor, insulin, α-glucosidase inhibitors, thiazolidinediones, and glucagon-like peptide-1 receptor agonist.
Study NCT06528405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin
Description: Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
Study NCT06528405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canagliflozin
Description: Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.